The role of DNA methylation in neoplasia is well-established, although its importance is only beginning to be appreciated. Hypermethylation is now being recognized s a major cause of gene inactivation in sporadic cancers, and is being found to play a more important role than mutations, in some cancers. The role of DNA methylation in endometrial carcinoma has not been investigated. Endometrial carcinoma hs the fifth leading cause of cancer in women worldwide, with approximately 150,000 cases diagnosed each year. We hypothesize that DNA methylation plays an important role in the pathogenesis of endometrial carcinoma, and propose to study four cancer-related genes, hMLH1, HMSH2, PTEN, and P16 for hypermethylation. We have available for our study a very well characterized population-based series of 316 endometrial carcinoma patients, collected over a period of 10 years, and for whom follow-up data is available. Methylation analysis of the mismatch repair genes, hMLH1 and hMSH2, will be tested, particularly in tumors that demonstrate microsatellite instability. Twenty percent of sporadic endometrial carcinoma tumors demonstrate microsatellite instability, but only a very small proportion of these are due to mutations in the mismatch repair genes. We hypothesize that hypermethylation of these genes are responsible for their inactivation and the subsequent microsatellite instability. We also propose to analyze the methylation status of two tumor suppressor genes, PTEN and p16, in our population of endometrial carcinoma patients, to determine their role in this disease. The PTEN and p16 genes are both good candidates for hypermethylation analysis in endometrial carcinoma, as mutations in the PTEN gene have recently implicated it in this disease, and inactivation of the p16 gene by hypermethylation appears to be a common finding in many other cancers. Our methylation studies will be complemented by mutation studies to determine the comparative role of mutation and methylation in gene inactivation. We will also study the effect of hypermethylation of our four candidate genes on prognosis. These studies should elucidate the role that DNA methylation plays in endometrial carcinoma, further our understanding of the molecular pathogenesis of this disorder, and establish markers that can be used for its diagnosis and prognosis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Research Grants (R03)
Project #
5R03CA081652-02
Application #
6173957
Study Section
Subcommittee G - Education (NCI)
Program Officer
Verma, Mukesh
Project Start
1999-07-01
Project End
2002-06-30
Budget Start
2000-07-01
Budget End
2002-06-30
Support Year
2
Fiscal Year
2000
Total Cost
$75,500
Indirect Cost
Name
University of Chicago
Department
Genetics
Type
Schools of Arts and Sciences
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Salvesen, Helga B; Kumar, Rajiv; Stefansson, Ingunn et al. (2005) Low frequency of BRAF and CDKN2A mutations in endometrial cancer. Int J Cancer 115:930-4
Salvesen, Helga B; Stefansson, Ingunn; Kretzschmar, Ellen I et al. (2004) Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression. Int J Oncol 25:1615-23
Salvesen, Helga B; Stefansson, Ingunn; Kalvenes, May Britt et al. (2002) Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma. Cancer 94:2185-91
Stefansson, Ingunn; Akslen, Lars A; MacDonald, Nicola et al. (2002) Loss of hMSH2 and hMSH6 expression is frequent in sporadic endometrial carcinomas with microsatellite instability: a population-based study. Clin Cancer Res 8:138-43
Salvesen, H B; MacDonald, N; Ryan, A et al. (2001) PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int J Cancer 91:22-6
Salvesen, H B; MacDonald, N; Ryan, A et al. (2000) Methylation of hMLH1 in a population-based series of endometrial carcinomas. Clin Cancer Res 6:3607-13
Salvesen, H B; Das, S; Akslen, L A (2000) Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis. Clin Cancer Res 6:153-9